Capsule Summary Slidesets

Share

Program Content

Activities

  • KRYSTAL-1
    KRYSTAL-1 Trial of Adagrasib in Patients With Previously Treated Advanced KRASG12C-Mutated NSCLC: Analysis of Registrational Phase II Cohort
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2022

    Expires: June 05, 2023

    View Activity
  • TACTI-002
    Phase II TACTI-002 Trial: Updated Results With Eftilagimod Alpha Plus Pembrolizumab as First-line Therapy in Advanced NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2022

    Expires: June 06, 2023

    View Activity
  • ATLANTIS Lurbinectedin Monotherapy
    ATLANTIS: Analysis of Outcomes With Single-Agent Lurbinectedin After Lurbinectedin + Doxorubicin in Relapsed SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2022

    Expires: June 07, 2023

    View Activity
  • OPAL: 1L Osi + CT in NSCLC
    OPAL: Phase II Trial of First-line Osimertinib Plus Platinum-Based Doublet Chemotherapy in EGFR-Mutated Advanced NSCLC
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

    View Activity
  • Patritumab Deruxtecan in Adv NSCLC
    Phase I Trial of Patritumab Deruxtecan for Previously Treated Advanced NSCLC Without EGFR Activating Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

    View Activity
  • SKYSCRAPER-02
    SKYSCRAPER-02: Phase III Trial of First-line Atezolizumab + Carboplatin/Etoposide ± Tiragolumab, an Anti-TIGIT Antibody, in ES-SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2022

    Expires: June 08, 2023

    View Activity
  • CHRYSALIS: Ami for <i>MET</i>ex14+ NSCLC
    CHRYSALIS: Updated Phase I Trial Results of Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

    View Activity
  • NADIM II: Neoadj Nivo + CT
    NADIM II: Phase II Trial of Neoadjuvant Nivolumab + Chemotherapy vs Chemotherapy in Resectable Stage IIIA/B NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

    View Activity
  • CLN-081: <i>EGFR</i> ex20ins+ NSCLC
    Updated Results of a Phase I/IIa Trial of CLN-081, a Selective EGFR TKI, in Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

    View Activity
  • CheckMate 816 Post Hoc EFS Analysis
    CheckMate 816: Association of Pathologic Regression With EFS for Neoadjuvant Nivolumab + CT in Resectable NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2022

    Expires: June 09, 2023

    View Activity
  • KRYSTAL-1 CNS Cohort
    KRYSTAL-1: Phase Ib Report of Adagrasib Activity in Patients With KRAS G12C–Mutated NSCLC and Active, Untreated CNS Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2022

    Expires: June 12, 2023

    View Activity
  • CHRYSALIS-2 Update
    CHRYSALIS-2: Update of Amivantamab + Lazertinib in EGFR-Mutant NSCLC After Progression on Osimertinib and Chemotherapy
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2022

    Expires: June 13, 2023

    View Activity
  • ATEZO-BRAIN Update
    Phase II ATEZO-BRAIN: Updated Results With Atezolizumab + Carboplatin/Pemetrexed in Advanced Nonsquamous NSCLC With Untreated Brain Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 16, 2022

    Expires: June 15, 2023

    View Activity

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab